JO
Publicaties op Oncologisch.com
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final totale...
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final totale overleving re...
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostat...
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant...
Talazoparib plus enzalutamide bij mCRPC: TALAPRO-2 veiligheid
Nivolumab plus gemcitabine-cisplatine bij gevorderd urotheelcarcinoom: CheckMate 901 fase III
Talazoparib plus enzalutamide bij eerstelijns mCRPC: TALAPRO-2 fase III